Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ: FBLG )

2.310 +0.210 (+10.00%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,050
Open 2.110
Bid (Size) 2.000 (1)
Ask (Size) 2.450 (5)
Prev. Close 2.100
Today's Range 2.110 - 2.330
52wk Range 1.078 - 55.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FibroBiologics Announces $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-92.06%
-92.06%
1 Month
-18.95%
-18.95%
3 Month
-20.89%
-20.89%
6 Month
-53.80%
-53.80%
1 Year
-92.06%
-92.06%

More News

Read More
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Engages Southern Star Research as CRO in Australia
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Files 2024 Second Quarter Report
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Set to Join Russell 2000® Index
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.